SXTC VS NBY Stock Comparison

PerformanceTechnicalsProfitVolatilityAnalyst Price TargetsEarnings
PerformanceTechnicalsProfitVolatilityAnalyst Price TargetsEarnings

Performance

SXTC
10/100

SXTC returned -87.22% in the last 12 months. Based on SPY's performance of -11.50%, its performance is below average giving it a score of 10 of 100.

NBY
10/100

NBY returned -88.00% in the last 12 months. Based on SPY's performance of -13.09%, its performance is below average giving it a score of 10 of 100.

Technicals

SXTC
21/100

SXTC receives a 21 of 100 based on 14 indicators. 2 are bullish, 10 are bearish.

NBY
21/100

NBY receives a 21 of 100 based on 14 indicators. 2 are bullish, 10 are bearish.

Profit

SXTC
63/100

Out of the last 8 quarters, SXTC has had 7 profitable quarters and has increased their profits year over year on 2 of them.

NBY
10/100

Out of the last 20 quarters, NBY has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

SXTC
40/100

SXTC has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.

NBY
58/100

NBY has had a higher than average amount of volatility over the last 12 months giving it a score of 57 of 100.

Analyst Price Targets

SXTC

"Analyst Price Targets" not found for SXTC

NBY
75/100

4 analysts offer 12-month price targets for NBY. Together, they have an average target of 0, the most optimistic target put NBY at 0 within 12-months and the most pessimistic has NBY at 0.

Earnings

SXTC

"Earnings" not found for SXTC

NBY
10/100

NBY has missed earnings 9 times in the last 20 quarters.

All score calculations are broken down here to help you make more informed investing decisions

China SXT Pharmaceuticals, Inc. Ordinary Shares Summary

Nasdaq / SXTC
Healthcare
Drug Manufacturers - Specialty & Generic
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets (TCMP) in China. The company offers advanced, fine, and regular TCMP products, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. As of March 31, 2022, it had an end-customer base of 68 pharmaceutical companies, 14 chain pharmacies, and 20 hospitals in 10 provinces and municipalities in China. The company was founded in 2005 and is headquartered in Taizhou, China.

NovaBay Pharmaceuticals, Inc. Summary

Healthcare
Biotechnology
NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.